These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 21286011)

  • 21. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
    Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
    Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Application of DNA methyltransferase inhibitors for myelodysplastic syndrome].
    Lü XY; Du YX; Dai ZH; Liu M; Liu XY; Zhang KL
    Yi Chuan; 2013 Feb; 35(2):136-40. PubMed ID: 23448925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DNA methyltransferase inhibitors in myelodysplastic syndrome.
    Silverman LR
    Best Pract Res Clin Haematol; 2004 Dec; 17(4):585-94. PubMed ID: 15494296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
    Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
    Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
    Silverman LR; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome.
    Asano M; Ohyashiki JH; Kobayashi-Kawana C; Umezu T; Imanishi S; Azuma K; Akahane D; Fujimoto H; Ito Y; Ohyashiki K
    Drug Des Devel Ther; 2019; 13():1821-1833. PubMed ID: 31239639
    [No Abstract]   [Full Text] [Related]  

  • 29. [Demethylating medication in myelodysplastic syndrome].
    Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Methylation of FHIT gene promoter region in DNA from plasma of patients with myelodysplastic syndromes and demethylating effect of decitabine].
    Deng YF; Zhang L; Zhang XQ; Hu MQ; Dai D; Zhang XZ; Xu YL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1144-8. PubMed ID: 23114136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.
    Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
    Oncotarget; 2017 Apr; 8(17):28812-28825. PubMed ID: 28427179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
    Leone G; Voso MT; Teofili L; Lübbert M
    Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
    Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
    Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of methylation changes in 9p21 region in patients with myelodysplastic syndromes and acute myeloid leukemia.
    Cechova H; Lassuthova P; Novakova L; Belickova M; Stemberkova R; Jencik J; Stankova M; Hrabakova P; Pegova K; Zizkova H; Cermak J
    Neoplasma; 2012; 59(2):168-74. PubMed ID: 22248274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Analysis of DNA Methylation in CD34+ Hematopoietic Progenitors in Myelodysplastic Syndrome.
    Wong YF; Micklem CN; Taguchi M; Itonaga H; Sawayama Y; Imanishi D; Nishikawa S; Miyazaki Y; Jakt LM
    Stem Cells Transl Med; 2014 Oct; 3(10):1188-98. PubMed ID: 25122688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
    Steensma DP; Stone RM
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
    Gore SD
    J Natl Compr Canc Netw; 2006 Jan; 4(1):83-90. PubMed ID: 16403407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine in myelodysplastic syndromes.
    Saba HI; Wijermans PW
    Semin Hematol; 2005 Jul; 42(3 Suppl 2):S23-31. PubMed ID: 16015501
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.
    Lyons J; Bayar E; Fine G; McCullar M; Rolens R; Rubinfeld J; Rosenfeld C
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1442-50. PubMed ID: 14763130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.